Sorrento Therapeutics Overview
- Status
-
Public
- Employees
-
949
- Stock Symbol
-
SRNE
- Investments
-
24
Sorrento Therapeutics General Information
Description
Sorrento Therapeutics Inc is a clinical and commercial-stage biopharmaceutical company developing a portfolio of next-generation treatments for three major therapeutic areas: cancer, infectious disease, and pain. Its multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (G-MAB library), immuno-cellular therapies (DAR-T), antibody-drug conjugates (ADCs), and oncolytic virus (Seprehvec). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including COVI-AMG, COVIDROPS, COVISHIELD, FUJOVEE (Abivertinib), and OQORY (Covi-MSC), and diagnostic test solutions, including COVITRACK and COVIMARK.
Contact Information
Website
www.sorrentotherapeutics.comCorporate Office
- 9380 Judicial Drive
- San Diego, CA 92121
- United States
Corporate Office
- 9380 Judicial Drive
- San Diego, CA 92121
- United States
Sorrento Therapeutics Stock Performance
As of 17-Jul-2025, Sorrento Therapeutics’s current market cap is $882K.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $882K | 124K |
Sorrento Therapeutics Financials Summary
As of 30-Jun-2023, Sorrento Therapeutics has a trailing 12-month revenue of $64.3M.
|
In Thousands, USD |
TTM 30-Jun-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 |
|---|---|---|---|---|
| EV | 314,667 | 466,796 | 1,464,173 | 1,955,590 |
| Revenue | 64,270 | 62,839 | 52,904 | 39,986 |
| EBITDA | (532,019) | (539,928) | (439,842) | (279,416) |
| Net Income | (547,997) | (572,843) | (428,325) | (298,461) |
| Total Assets | 456,692 | 472,840 | 694,818 | 535,822 |
| Total Debt | 207,600 | 134,504 | 237,577 | 169,393 |
Sorrento Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Sorrento Therapeutics Comparisons
Industry
Financing
Details
Sorrento Therapeutics Competitors (69)
One of Sorrento Therapeutics’s 69 competitors is ImmunityBio, a Formerly VC-backed company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| ImmunityBio | Formerly VC-backed | San Diego, CA | ||||
| Immunocore | Formerly VC-backed | Abingdon, United Kingdom | ||||
| NexImmune | Formerly VC-backed | Gaithersburg, MD | ||||
| Iovance Biotherapeutics | Corporation | San Carlos, CA | ||||
| Inovio Pharmaceuticals | Corporation | Plymouth Meeting, PA |
Sorrento Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Sorrento Therapeutics Patents
Sorrento Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-3228858-A1 | Therapeutic agents targeting the lymphatic system | Pending | 18-Aug-2021 | ||
| JP-2024531337-A | Therapeutics that target the lymphatic system | Pending | 18-Aug-2021 | ||
| CA-3221925-A1 | Method of treating cancer by administration of an anti-pd-1 or anti-pd-l1 therapeutic agent via a lymphatic microneedle delivery device | Pending | 09-Jun-2021 | ||
| JP-2024522623-A | Methods for treating cancer by administering anti-pd-1 or anti-pd-l1 therapeutics via a lymphatic microneedle delivery device | Pending | 09-Jun-2021 | ||
| CA-3219312-A1 | Presurgical perineural administration of resiniferatoxin for reduction of post-operative pain | Pending | 18-May-2021 | A61K31/357 |
Sorrento Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Sorrento Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Sorrento Therapeutics Investments & Acquisitions (24)
Sorrento Therapeutics’s most recent deal was a Merger/Acquisition with Zhengzhou Fortune Bioscience. The deal was made on 17-Feb-2022.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Zhengzhou Fortune Bioscience | 17-Feb-2022 | Merger/Acquisition | Diagnostic Equipment | ||
| Virex Health | 01-Feb-2022 | Merger/Acquisition | Diagnostic Equipment | ||
| Aardvark Therapeutics | 01-Aug-2021 | Early Stage VC | Drug Discovery | ||
| Celularity | 16-Jul-2021 | PIPE | Drug Discovery | ||
| ACEA Therapeutics | 01-Jun-2021 | Merger/Acquisition | Drug Discovery |
Sorrento Therapeutics ESG
Risk Overview
Risk Rating
Updated December, 07, 2022
35.9 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,842
Rank
Percentile
Pharmaceuticals
Industry
of 898
Rank
Percentile
Biotechnology
Subindustry
of 402
Rank
Percentile
Sorrento Therapeutics Exits (7)
Sorrento Therapeutics’s most recent exit was on 01-Aug-2021 from Aardvark Therapeutics. The exit was categorized as with 8 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Aardvark Therapeutics | 01-Aug-2021 | Completed |
|
||
| Pulsar Therapeutics | 13-May-2020 | Completed |
|
||
| SCILEX Holding | 08-Nov-2016 | Completed |
|
||
| ImmuneOncia | 07-Apr-2016 | Completed |
|
||
| NantKwest | 26-Dec-2014 | Later Stage VC | Completed |
|
Sorrento Therapeutics Affiliates
Subsidiaries (7)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| SmartPharm Therapeutics | Cambridge, MA | 2018 | |
| Semnur Pharmaceuticals | Palo Alto, CA | 2013 | |
| Ancora Medical | Menlo Park, CA | 2013 | |
| Nant-paclitaxel | Fountain Valley, CA | 2012 | |
| Zhengzhou Fortune Bioscience | Zhengzhou, China | 2003 |
Sorrento Therapeutics FAQs
-
Where is Sorrento Therapeutics headquartered?
Sorrento Therapeutics is headquartered in San Diego, CA.
-
What is the size of Sorrento Therapeutics?
Sorrento Therapeutics has 949 total employees.
-
What industry is Sorrento Therapeutics in?
Sorrento Therapeutics’s primary industry is Biotechnology.
-
Is Sorrento Therapeutics a private or public company?
Sorrento Therapeutics is a Public company.
-
What is Sorrento Therapeutics’s stock symbol?
The ticker symbol for Sorrento Therapeutics is SRNE.
-
What is the current market cap of Sorrento Therapeutics?
The current market capitalization of Sorrento Therapeutics is $882K.
-
What is Sorrento Therapeutics’s current revenue?
The trailing twelve month revenue for Sorrento Therapeutics is $64.3M.
-
Who are Sorrento Therapeutics’s competitors?
ImmunityBio, Immunocore, NexImmune, Iovance Biotherapeutics, and Inovio Pharmaceuticals are some of the 69 competitors of Sorrento Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
